



DEPARTMENT OF HEALTH & HUMAN SERVICES

---

National Institutes of Health  
Bethesda, Maryland 20892

February 18, 2011

S. Claiborne Johnston, M.D., Ph.D.  
Professor and Associate Vice Chancellor of Research  
University of California, San Francisco  
505 Parnassus Avenue, Box 0114, M798  
San Francisco, CA 94143-0114

Dear Dr. Johnston:

I am writing to confirm that the NINDS-appointed Data and Safety Monitoring Board (DSMB) for your clinical trial, "Platelet-Oriented Inhibition in New TIA and minor ischemic stroke" (POINT), met in Los Angeles on February 11, 2011 to review all interim data from the trial. The DSMB found no issues of concern regarding safety or study implementation, and thus recommended the study proceed as planned.

The DSMB will meet by teleconference in approximately six months to perform the next interim review.

Sincerely,

A handwritten signature in black ink, appearing to read "Peter R. Gilbert".

Peter R. Gilbert, Sc.M.  
Clinical Research Project Manager  
Office of Clinical Research  
National Institute of Neurological Disorders and Stroke  
National Institutes of Health  
6001 Executive Boulevard, Suite 2202  
Bethesda, MD 20892-9525